Trust Co. of Toledo NA OH Purchases 225 Shares of Gilead Sciences, Inc. (GILD)
Trust Co. of Toledo NA OH boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 32,643 shares of the biopharmaceutical company’s stock after buying an additional 225 shares during the period. Trust Co. of Toledo NA OH’s holdings in Gilead Sciences were worth $2,582,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Bank of Montreal Can purchased a new position in Gilead Sciences during the second quarter valued at $427,750,000. Capital World Investors raised its stake in shares of Gilead Sciences by 28.3% in the second quarter. Capital World Investors now owns 15,318,948 shares of the biopharmaceutical company’s stock valued at $1,277,907,000 after buying an additional 3,380,000 shares during the last quarter. Boston Partners raised its stake in shares of Gilead Sciences by 51.7% in the third quarter. Boston Partners now owns 9,855,682 shares of the biopharmaceutical company’s stock valued at $779,781,000 after buying an additional 3,358,289 shares during the last quarter. Parnassus Investments CA raised its stake in shares of Gilead Sciences by 45.4% in the second quarter. Parnassus Investments CA now owns 8,460,484 shares of the biopharmaceutical company’s stock valued at $705,774,000 after buying an additional 2,640,284 shares during the last quarter. Finally, Alliancebernstein L.P. raised its stake in shares of Gilead Sciences by 17.0% in the second quarter. Alliancebernstein L.P. now owns 13,346,714 shares of the biopharmaceutical company’s stock valued at $1,113,383,000 after buying an additional 1,942,138 shares during the last quarter. 73.43% of the stock is owned by hedge funds and other institutional investors.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) traded down 0.19% during midday trading on Friday, hitting $73.22. The company had a trading volume of 4,768,311 shares. Gilead Sciences, Inc. has a 12 month low of $70.83 and a 12 month high of $103.10. The company has a market cap of $96.46 billion, a price-to-earnings ratio of 6.77 and a beta of 1.20. The stock’s 50-day moving average price is $73.96 and its 200-day moving average price is $77.97.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.87 by $0.12. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. The business had revenue of $7.40 billion for the quarter, compared to analysts’ expectations of $7.47 billion. During the same quarter in the prior year, the firm earned $3.22 earnings per share. Gilead Sciences’s revenue for the quarter was down 9.6% compared to the same quarter last year. On average, equities research analysts forecast that Gilead Sciences, Inc. will post $11.47 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 29th. Shareholders of record on Thursday, December 15th were issued a dividend of $0.47 per share. The ex-dividend date of this dividend was Tuesday, December 13th. This represents a $1.88 annualized dividend and a yield of 2.56%. Gilead Sciences’s dividend payout ratio is presently 17.44%.
Several brokerages recently commented on GILD. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a report on Sunday, November 6th. Cowen and Company set a $120.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Sunday, October 23rd. Robert W. Baird reissued an “outperform” rating and issued a $100.00 price target on shares of Gilead Sciences in a report on Wednesday, December 21st. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Monday, September 26th. Finally, Jefferies Group reissued a “buy” rating and issued a $91.00 price target on shares of Gilead Sciences in a report on Thursday, September 22nd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $96.18.
In other news, Director John W. Madigan sold 105,000 shares of the business’s stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $74.86, for a total value of $7,860,300.00. Following the completion of the sale, the director now directly owns 121,761 shares in the company, valued at approximately $9,115,028.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John C. Martin sold 73,337 shares of the business’s stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $73.59, for a total value of $5,396,869.83. Following the completion of the sale, the insider now owns 3,204,433 shares of the company’s stock, valued at $235,814,224.47. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.